Delandistrogene moxeparvovec demonstrated a manageable safety profile across clinical trials for Duchenne muscular dystrophy (DMD), with most adverse events emerging within 90 days of infusion. Barry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback